Maeda Hiroshi, Miura Kouichi, Morimoto Naoki, Watanabe Shunji, Tsukui Mamiko, Takaoka Yoshinari, Nomoto Hiroaki, Goka Rie, Sato Naoto, Morishima Kazue, Sakuma Yasunaru, Sata Naohiro, Fukushima Noriyoshi, Isoda Norio, Yamamoto Hironori
Department of Medicine, Division of Gastroenterology, Jichi Medical University, 3311-1 Yakushiji Shimotsuke, Tochigi 329-0498, Japan.
Department of Surgery, Division of Gastrointestinal, General and Transplant Surgery, Jichi Medical University, 3311-1 Yakushiji Shimotsuke, Tochigi 329-0498, Japan.
Cancers (Basel). 2022 Jan 31;14(3):752. doi: 10.3390/cancers14030752.
Conventional therapies, including chemoembolization and radiation therapy, have been expected to prolong the prognosis of hepatocellular carcinoma (HCC) patients with extrahepatic metastases, which remains poor. However, little information is available on the efficacy of conventional therapies for such patients under tyrosine kinase inhibitor (TKI) treatment.
We retrospectively investigated 127 HCC patients with extrahepatic metastases, who were divided into the non-TKI (conventional therapies) and TKI groups and further subdivided into the TKI alone and TKI plus conventional therapies groups. Conventional therapies included transcatheter arterial chemoembolization, cisplatin-based chemotherapy, radiation, surgery, and UFT, an oral chemotherapeutic agent.
The median of the overall survival (OS) of the 127 patients with extrahepatic metastases was 7.0 months. Meanwhile, the median OS of the TKI and non-TKI groups was 12.1 and 4.1 months, respectively. Imitating TKI after diagnosing metastases promoted a favorable increase in OS. Among the TKI group, the median OS in the TKI alone group was 8.9 months. TKI plus conventional therapies promoted no improvement in OS after adjusting for the patients' background data.
TKI promoted a better OS in HCC patients with extrahepatic metastases compared to conventional therapies. However, TKI plus conventional therapies promoted no improvement in the prognosis of such patients.
包括化疗栓塞和放射治疗在内的传统疗法一直被期望能延长伴有肝外转移的肝细胞癌（HCC）患者的预后，但其预后仍然较差。然而，关于酪氨酸激酶抑制剂（TKI）治疗下传统疗法对此类患者疗效的信息却很少。
我们回顾性研究了127例伴有肝外转移的HCC患者，将其分为非TKI（传统疗法）组和TKI组，并进一步细分为单纯TKI组和TKI联合传统疗法组。传统疗法包括经动脉化疗栓塞、基于顺铂的化疗、放疗、手术以及口服化疗药物优福定（UFT）。
127例伴有肝外转移患者的总生存期（OS）中位数为7.0个月。同时，TKI组和非TKI组的OS中位数分别为12.1个月和4.1个月。转移诊断后采用TKI可使OS有良好的增加。在TKI组中，单纯TKI组的OS中位数为8.9个月。在对患者背景数据进行调整后，TKI联合传统疗法并未使OS得到改善。
与传统疗法相比，TKI可使伴有肝外转移的HCC患者获得更好的OS。然而，TKI联合传统疗法并未改善此类患者的预后。
